GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » Operating Margin %
中文

Biocept (Biocept) Operating Margin %

: -1,038.03% (As of Jun. 2023)
View and export this data going back to 2014. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Biocept's Operating Income for the three months ended in Jun. 2023 was $-6.11 Mil. Biocept's Revenue for the three months ended in Jun. 2023 was $0.59 Mil. Therefore, Biocept's Operating Margin % for the quarter that ended in Jun. 2023 was -1,038.03%.

Good Sign:

Biocept Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Biocept's Operating Margin % or its related term are showing as below:

BIOCQ' s Operating Margin % Range Over the Past 10 Years
Min: -10431.58   Med: -488.5   Max: -3.93
Current: -2445.28


BIOCQ's Operating Margin % is ranked worse than
94.25% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.15 vs BIOCQ: -2445.28

Biocept's 5-Year Average Operating Margin % Growth Rate was 49.40% per year.

Biocept's Operating Income for the three months ended in Jun. 2023 was $-6.11 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-33.16 Mil.


Biocept Operating Margin % Historical Data

The historical data trend for Biocept's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only -746.43 -417.02 -56.33 -3.93 -123.69

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -169.94 -1,008.64 1,072.18 -1,054.68 -1,038.03

Competitive Comparison

For the Diagnostics & Research subindustry, Biocept's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept Operating Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Biocept's Operating Margin % falls into.



Biocept Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Biocept's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-31.983 / 25.858
=-123.69 %

Biocept's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-6.114 / 0.589
=-1,038.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocept  (OTCPK:BIOCQ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Biocept Operating Margin % Related Terms

Thank you for viewing the detailed overview of Biocept's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (Biocept) Business Description

Traded in Other Exchanges
N/A
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Executives
Robert Walsh officer: VP, Controller 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock director C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand officer: Chief Operations Officer C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor officer: Sr. V.P., General Counsel C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale director, officer: EXECUTIVE CHAIRMAN 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales director C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein director 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan officer: Chief Med Off & Med. Director 2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory officer: Sr. VP Corp. Development C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick officer: SVP, Chief Commercial Officer 2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry officer: Sr VP Comm. Operations
Marsha Alpert Chandler director 7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall director, officer: CEO AND PRESIDENT 4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy officer: CFO, Sr V.P. Operations & Sec. 5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121